bluuebunny/crossref_metadata_2025_split huggingface dataset:
P1268 Sexual health challenges in inflammatory bowel disease: A population-based cross-sectional study
Authors: Larimore C F , Jacobsen H , Larsen L , Graugaard C , Andersson M , Frisch M 
Published: January 2025

Abstract

Background
Individuals with inflammatory bowel disease (IBD) may experience impaired body image, poorer quality of life, and reduced sexual functioning compared to the general population. However, variations in sexual health across the diverse disease spectrum of IBD must be expected. This study examined sexual challenges and dysfunctions in Danish individuals with and without IBD.

Methods
In this population-based cross-sectional study, 62,675 participants from the nationally representative Project SEXUS cohort study (www.projektsexus.dk) were linked to the Danish National Patient Register to identify participants (n=655) with a first IBD diagnosis recorded between 1996 and 2017 (n=437 with ulcerative colitis (UC); n=218 with Crohn’s disease (CD)). In sex-specific analyses, the prevalence of sex life challenges and dysfunctions in participants with and without IBD and associated, confounder-adjusted odds ratios (aOR) with 95% confidence intervals (CI) were assessed. Active disease was defined by a fecal calprotectin concentration of &gt;150 μg/g.

Results
There were few differences in how individuals with and without IBD assessed their overall sex life and current relationship quality. However, when compared with individuals without IBD, both men and women with UC were significantly more likely to report hypoactive sexual desire disorder (men: aOR=2.18; 95% CI: 1.13-4.19; women: aOR=1.66; 95% CI: 1.04-2.66), and women with UC more often reported genital pain dysfunction (aOR=2.30; 95% CI: 1.26-4.19). In IBD subgroup-specific analyses, men with active UC were more often affected by hypoactive sexual desire disorder (aOR=10.44; 95% CI: 2.29-47.57), men with UC and a stoma more often reported erectile dysfunction (aOR=22.21; 95% CI: 3.26-151.47), and men with CD and a stoma more often reported orgasmic dysfunction (aOR=7.92; 95% CI: 1.02-61.78), when compared with men without IBD. Among women, those with active UC more often reported vaginal cramp dysfunction (aOR=12.30; 95% CI: 1.25-120.59), whereas women with CD complicated by perianal involvement more often experienced genital pain dysfunction (aOR=6.39; 95% CI: 1.04-39.17), when compared with women without IBD.

Conclusion
Individuals with UC and subgroups of patients with IBD with active disease, stoma, or perianal involvement face a significantly elevated risk of various sexual challenges and dysfunctions. Healthcare providers in gastroenterology should therefore remain attentive to these potential issues and offer appropriate counselling or treatment when needed.
P1269 Assessing the prevalence and incidence of recorded fatigue codes amongst IBD patients: A nationwide study from the epi-IIRN
Authors: Focht G , Buchuk R , Loewenberg Weisband Y , Ben-Tov A , Zacay G , Matz E , Dotan I , Paltiel O , Turner D ,   The epi-IIRN
Published: January 2025

Abstract

Background
Fatigue is a common and burdensome symptom experienced by patients with Inflammatory Bowel Diseases (IBD), yet it remains under-recognised and understudied. This study aimed to assess the prevalence and incidence of recorded fatigue in the first nationwide cohort investigation of this topic.

Methods
We utilised the epi-IIRN cohort, encompassing all IBD patients in Israel across the four Health Maintenance Organisations (HMOs), covering 98% of the population. These patients were matched to non-IBD controls (by birth year, sex, district, HMO). We included patients with IBD diagnosed from 2005 onwards and followed until June 2021. Fatigue was identified using ICD-9 codes for "Malaise and Fatigue" or "Chronic Fatigue". Patients with fatigue codes &gt;2 years prior to IBD diagnosis were excluded. Prevalence of fatigue codes was compared with matched non-IBD controls, and incidence rates were analysed using Kaplan-Meier survival curves. Associations with disease activity, reflected in blood tests, and other recorded comorbidities known to contribute to fatigue were explored. Predictors of fatigue in IBD patients were assessed using a multivariate Cox model.

Results
The study comprised of 32,908 IBD patients (18,555 with Crohn’s disease [56%]; 47% female; mean age at diagnosis 35.4±18.5 years) were matched to 74,688 controls. Fatigue was recorded in 6,210 (18.9%) IBD patients compared to 9,593 (12.8%) controls (OR=1.58, 95%CI 1.52–1.63; p&lt;0.001). Among IBD patients, fatigue was more frequent in females (OR=1.52, 95%CI 1.44–1.60). Time to fatigue onset was shorter in both male and female IBD patients compared to matched controls (p&lt;0.001; figure).
Fatigue rates were similar between Crohn’s disease (3,548 [19.1%]) and ulcerative colitis (2,662 [18.5%]; OR=1.04, 95%CI 0.98–1.10; p=0.2).
IBD patients with fatigue had higher rates of anaemia, iron deficiency, anxiety, depression, and sleep disorders compared to those without (Table).
In a multivariate Cox model, female sex, frequent physician visits, anaemia, sleep disorders, and steroid use were associated with fatigue. In contrast, the use of 5-ASA, immunomodulators, anti-TNFs, and vedolizumab was protective (figure). Disease severity, reflected by cluster analysis of blood tests (moderate vs mild and severe vs mild), was not independently associated with fatigue (HR=1.08 95%CI 1.01-1.15 and 0.94 95%CI 0.84-1.05 respectively).

Conclusion
In this nationwide, unselected cohort, fatigue was more frequently reported in IBD patients compared to controls and was associated with several disease-related and comorbid factors. The burden of fatigue is underscored by its strong association with anxiety, sleep disorders, and depression.
P1279 Associations of accelerometer-measured moderate-to-vigorous physical activity with bowel resection risk and mortality among individuals with inflammatory bowel disease: a prospective cohort study
Authors: He Z , Sun Y , Huang H , Liu Y , Dan L , Ruan X , Li Z , Wang X , Chen J , Bai Y 
Published: January 2025

Abstract

Background
There is limited consensus on physical activity recommendations for inflammatory bowel disease (IBD) patients due to insufficient high-quality evidence. We investigated the associations of accelerometer-measured moderate-to-vigorous physical activity (MVPA) with bowel resection risk and mortality among affected individuals.

Methods
We collected data from 1,303 UK Biobank participants with IBD diagnosis and device-measured physical activity. MVPA was classified based on data measured by wrist-worn accelerometers over a 7-day period. MVPA patterns were defined as inactive, active weekend warrior, and regularly active. Associations were estimated using multivariable Cox regression models.

Results
During a median follow-up of 7.8 years, 56 incident bowel resection cases and 86 deaths were documented. Compared to those with the lowest tertile, participants with the highest tertile of MVPA duration had lower risks of bowel resection (HR, 0.44; 95% CI, 0.22-0.86) and mortality (HR, 0.49; 95% CI, 0.27-0.89). MVPA duration is linearly associated with bowel resection (P non-linear = 0.13) while its dose-response relationship with mortality plateaus at approximately 58 min/day (P non-linear = 0.02). The active weekend warrior pattern was inversely associated with bowel resection (HR, 0.28; 95% CI, 0.12-0.65), the regularly active pattern was inversely associated with both bowel resection (HR, 0.37; 95% CI, 0.19-0.69) and mortality (HR, 0.53; 95% CI, 0.31-0.91) compared to the inactive.

Conclusion
Longer accelerometer-measured MVPA was associated with reduced bowel resection risk and mortality. The regularly active pattern may be the optimal choice for individuals with IBD, while the active weekend warrior pattern still provides health benefits compared to being inactive.
P1284 Prevalence of immune-mediated extraintestinal manifestations in paediatric Inflammatory Bowel Disease: a systematic review and meta-analysis
Authors: Colman R J , Vuyyuru S K , Solitano V , MacDonald J K , Ricciuto A , Berard R , Mohammed J , Ma C , Jairath V , Crowley E 
Published: January 2025

Abstract

Background
Concurrent immune-mediated extraintestinal manifestations (IM-EIMs; Table 1) are common in paediatric-onset inflammatory bowel disease (pIBD), but the overall epidemiology is unknown. This systematic review and meta-analysis aimed to summarise the prevalence and management of EIMs in pIBD.

Methods
MEDLINE, EMBASE and CENTRAL, clinicaltrials.gov and conference abstracts were searched up to May 6, 2024, for studies that included pIBD (2-17 years old) with secondarily diagnosed EIMs. The primary outcome included the prevalence of IM-EIMs among pIBD. Secondary outcomes included efficacy and adverse effects of treatment on EIMs. Meta-analysis included pooled proportions with DerSimonian-Laird random-effects analysis.

Results
The pooled proportion of IM-EIMs among pIBD was 8.4% (95% CI, 6.5-11.0%; I2=97%) among 53 eligible studies. The pooled proportion of IM-EIMs was 10.3% (95% CI, 7.3-13.8%; I2=95%) among 37 Crohn’s disease (CD) studies, compared to 11.3% (95% CI, 7.8-15.3%; I2=93%) among 39 ulcerative colitis (UC) studies. Enthesitis was the highest reported individual IM-EIM (23%, 95% CI, 4-50%; I2=94.7%) in pIBD. Arthritis was the second highest reported individual IM-EIM (8%, 95% CI, 6-10%; I2=96%) in pIBD, followed by primary sclerosing cholangitis (PSC) in UC (5%, 95% CI, 4-7%; I2=81%; Table 2). Uveitis, pyoderma gangrenosum, autoimmune hepatitis, and PSC in CD were the lowest reported IM-EIMs at 1% or less. The largest difference in reported proportions between IBD phenotypes was PSC, which was 4% higher in UC than CD. Only one eligible study described treatment response.

Conclusion
This meta-analysis identified that while musculoskeletal manifestations are relatively common, fewer than 5% of pIBD patients experience ophthalmological, dermatological, and hepatic IM-EIMs. There was significant methodological and statistical heterogeneity as expected for the relatively small number of individual paediatric studies and likely resulted in the large difference of pooled proportions between individual IM-EIMs. Multicentre collaborative efforts are needed to systematically describe the epidemiology and management outcomes of EIMs in pIBD in the current era of advanced therapies.
P1285 Incidence of venous thromboembolism in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis
Authors: Song J H , Shim S R , Kim D S , Koo H S , Huh K C 
Published: January 2025

Abstract

Background
Although the incidence and prevalence of inflammatory bowel disease (IBD) have been gradually increasing throughout Asia, the incidence of venous thromboembolism (VTE) in Asia is relatively lower than that in Western countries and is not well known. This study aimed to evaluate the incidence of VTE in Asian patients with IBD using a systematic review and meta-analysis.

Methods
Studies were identified through a literature search of the PubMed, Embase, and Cochrane databases (from inception inclusive April 2024) for English studies. The criteria for selecting the participants were as follows: (1) studies including patients with Crohn’s disease (CD) and Ulcerative colitis (UC) in the Asian population; (2) comparisons were specified as with a control group of non-IBD patients for comparative incidence; and (3) outcomes were measured by relative risks (RR) and hazard risk (HR) for VTE incidence in nationwide cohort studies. Three independent reviewers extracted published data using a standardized procedure in accordance with the reporting guidelines. A fixed-effects model was used to estimate pooled effect sizes. Meta-regression analyses were conducted to identify the potential moderating effects of VTE risk in patients with IBD.

Results
Five studies met the inclusion criteria. The pooled RR for overall VTE incidence in Asian patients with IBD compared to that in non-IBD patients was 2.065 (95% CI: 1.905–2.238). The heterogeneity test resulted in a p-value of 0.418 for the Cochrane Q statistics, and Higgins’ I2 was 0%. There was no statistical moderating effect of the variables (number of patients, mean age, female rate, CD proportion, country, and type of risk) on the outcomes.

Conclusion
In our systematic review and meta-analysis, the VTE incidence in Asian patients with IBD was higher than that in non-IBD patients (RR 2.065). It seemed reasonable to consider prophylaxis for VTE in hospitalized patients with IBD.
P1286 Prevalence, concordance and course of disease in first-degree relatives with Inflammatory Bowel Disease
Authors: Mantzaris MD- PhD- AGAF- FEBG- MACG G 
Published: January 2025

Abstract

Background
The prevalence, concordance for and severity of disease in first-degree relatives (FDRs) affected by IBD has been under-reported in Greece. The aim of this study was to assess the prevalence, concordance and course of disease in FDRs affected by IBD in a cohort of consecutive IBD patients.

Methods
Consecutive patients with ulcerative colitis (UC) and Crohn’s disease (CD) who were examined in a solo practice office between 1st January 2023 and 31st October 2024 were asked for the diagnosis of UC or CD in any FDG relative (parent/children, siblings). Identified FDR were interviewed separately. A detailed medical history and physical examination was obtained from case patients and identified FDRs with IBD regarding demographic, disease and treatment characteristics, including place of birth and inhabitance, neonatal feeding attitudes, smoking and additional social habits, disease phenotype, extra-intestinal manifestations, co-morbidities, laboratory tests, imaging, endoscopy and histology reports, received medical and/or surgical treatments, and treatment outcomes until the day of interview.

Results
Overall 602 patients [380 CD/222 UC (including 28 pouch patients), 306 females, median age 35 (range 17-77 years) were interviewed. Patients geographic origin was representative of all country’s regions. Thirty pairs of FDP patients were identified (5%): all Caucasians, 11 cases mother/daughter, 1 case father/daughter, 2 cases mother/son, 3 cases father/son and 13 sibling cases (table 1). There were more cases parents/daughter than parents/son (13 vs 4) and more cases in mother/daughter than mother/son FDRs (11 vs 2). The disease was concordant for 8/17 cases parent/children, especially for UC (5/8) and in 6/13 sibling cases, especially for CD (5/6 cases). The course of disease was mild in 8/30 (26.7%) cases (5 parent/children, only 1 was concordant for UC) and in 3 sibling cases (all discordant for CD). Eight patients (6 CD/2 UC) had undergone right hemi-colectomy (4), colectomy (2, colorectal cancer and acute severe UC, respectively), parianal CD (1) and J pouch (2). One case (mother-UC/child-CD) had J pouch and stoma, respectively.

Conclusion
In this cohort of consecutive IBD-FDRs the disease was more common in females and concordant in nearly 50% of the patients, especially in siblings. The course of IBD was rather aggressive and 73% of patients had been treated with advanced therapies and/or surgical interventions.
P1287 Comparative Analysis of IBD Management: Hospital Versus Community-based Care
Authors: Israel A , Sharif K , Lahat A 
Published: January 2025

Abstract

Background
Our study aimed to compare disease characteristics, medication utilization, procedures performed, and hospitalizations between IBD patients treated in hospital and community settings using the Leumit Health Service database.

Methods
A retrospective cohort study was conducted using data from the Leumit Health Service, comprising 3020 patients diagnosed with IBD fBetween 2010 -2019. Patients were divided based on primary care setting: hospital-based or community-based. Data included demographic characteristics, disease type, medication usage, procedures, and outcomes.

Results
Overall 3020 patients were included, of them 1627 ( 54%) were community treated, and 1741 (57%) suffered from CD. Hospital-treated patients were significantly younger (49.4 ± 18.4 vs 40.4 ± 18.7,p&lt;0.001 ), had higher rates of Crohn’s disease (45.9 % vs 71.4 %, p&lt;0.001), exhibited higher inflammatory markers (calprotectin 768 ± 2182 vs 1305 ± 2526, p &lt;0.001) , lower albumin ( 4.23 ± 0.27vs 4.12 ± 0.32, p&lt;0.001)and Hemoglobin levels (13.4 ± 1.6 vs 12.9 ± 1.6, p &lt;0.001) , and lower BMI (26.2 ± 5.3 vs 24.6 ± 5.6, p&lt;0.001) compared to community-treated patients. Hospital-treated patients had more endoscopic procedures, higher medication utilization rates, shorter treatment durations, and increased hospitalizations occurrence (12.1 % vs 23.6 %, p&lt;0.001) , length (0.67 ± 3.34 vs 1.45 ± 5.88, p&lt;0.001), and colectomies (4.73 % vs 15.8 %,p&lt;0.001). Table 1 displays emergency room (ER) visits, hospitalizations and colectomy among study groups,and Figure 1 displays medical treatments among study groups.

Conclusion
Hospital-based care is associated with more aggressive disease and intensive interventions, while community-based care may reflect milder disease and conservative management. Integrating specialized care models and personalized approaches across settings can optimize patient outcomes and healthcare delivery for IBD management.
P1299 Modulation of miR-31-5p expression in patients with Ulcerative Colitis treated with infliximab
Authors: Pereira J , Grillo T , Oliveira E , Baima J , Quaglio A E , Costa E , Di Stasi L , Sassaki L 
Published: January 2025

Abstract

Background
Biological therapy has revolutionized the treatment of Ulcerative Colitis (UC), but biomarkers that predict response are still lacking. MicroRNAs (miRNAs) are small non-coding RNA molecules that participate in cellular processes such as proliferation, differentiation, migration, maturation and apoptosis, and therefore are related to immune regulation in physiological and pathological conditions such as Inflammatory Bowel Diseases. Therefore, the objective of the study is to investigate the expression profile of miRNAs in responding and non-responding patients treated with Infliximab and to identify a profile of miRNAs that predict therapeutic response.

Methods
Twelve miRNAs: miR-21-5p, miR-31-5p, miR-192-3p, miR-192-5p, miR-215-5p, miR-326, miR-378-3p, miR-378-5p, miR-422a, miR-429, miR-551a and miR-1258-3p were evaluated in naïve patients with UC before and after treatment with Infliximab (week 54). MiRNA was extracted from formalin-fixed, paraffin-embedded (FFPE) colon tissue and qRT-PCR was performed from 12 patients, of which: 5 responding and 7 non-responding, both groups evaluated pre and post treatment (n=24 samples).

Results
Decreased expression was found for miR-31-5p (p=0.03) when comparing responding patients pre and post treatment, meanwhile miR-192-5p (p &gt; 0.99) and miR-378-3p (p &gt; 0.99) were suggestive but not statistically different. The other miRNAs had not had expressive results.

Conclusion
Infliximab-responding patients with UC presented decreased expression of miR-31-5p. MiR-31-5p regulates IL-25 and activates Th1/Th17 mediated inflammation in UC. Therefore, our results reinforce the importance of miR-31-5p expression in UC and indicate a relationship between this miRNA and the effectiveness of the treatment.
P1303 A machine – learning approach of therapeutic response prediction for Ustekinumab in ulcerative colitis
Authors: Koustenis K , Dovrolis N , Viazis N , Ioannou A , Bamias G , Karamanolis G , Gazouli M 
Published: January 2025

Abstract

Background
Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23, is a promising therapeutic approach in patients with ulcerative colitis (UC), but predicting treatment response remains a challenge. In the present study, we focused to identify prognostic response markers to ustekinumab in patients with active UC, utilizing mucosal transcriptome information and machine-learning approaches.

Methods
We used 36 drug naive UC patients initiating treatment with ustekinumab. Colonic mucosal biopsies were obtained before treatment initiation. The gene expression analysis was performed using a microarray panel of 84 inflammation related genes. A differential gene expression analysis (DGEA), correlation analysis, and network centrality analysis on co-expression networks were performed to identify potential biomarkers. Additionally, machine learning (ML) models were employed to predict treatment response based on gene expression data.

Results
The genes BCL6, CXCL5, and FASLG, were among the significantly upregulated, while IL23A and IL23R were downregulated in non-responders compared to responders. The co-expression analysis revealed distinct patterns between responders and non-responders. The ML algorithms demonstrated a high predictive power, emphasizing the significance of the IL23R, IL23A, and BCL6 genes.

Conclusion
Through a variety of computational approaches, our study indicates the predictive power of mucosal expression data in predicting patient response to ustekinumab treatment.
P1306 Impact of HLA-DQA1*05 genotype in immunogenicity and response to treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease patients
Authors: Moreno Torres V , Mira C , Madero-Velázquez L , Muñoz R , Belén-Galipienso O , Cameo J I , Bernal L , García-Trueba A , Sempere L , Gutiérrez-Casbas A 
Published: January 2025

Abstract

Background
Carrying the HLA-DQA1*05 gene has been linked to a higher risk of developing immunogenicity in patients with inflammatory bowel disease (IBD) who are treated with tumor necrosis factor-alpha (TNF-a) inhibitors. However, studies have shown inconsistent evidence regarding its connection to a loss of response or adverse events in patients with IBD. The aim is to determine the impact of carriage of HLA-DQA1*05 allele on effectiveness, drug persistence and safety in patients diagnosed with IBD who had received antiTNF-a inhibitors.

Methods
Retrospective, single-center cohort study including IBD patients who had received anti-TNF therapy. The HLA-DQA1*05 allele was determined retrospectively from a saliva sample (kit OGD-600 de DNA Genotek Oragene) and DNA extraction with the Maxwell® RSC-Stabilized Saliva DNA kits. We evaluate drug persistence, withdrawal of antiTNF-a, clinical response/remission, primary and secondary loss of response, through antiTNF levels, development of antiTNF antibodies and adverse events in patients distributed by HLA-DQA1*05 allele presence.

Results
A total of 82 patients were included. Baseline characteristics are detailed in Table 1. HLA-DQA1*05 was positive in 35/82 (42.7%) patients. Sixty-three patients (63%) received infliximab (IFX) and 19/82(23.2%) adalimumab. AntiTNF was the first advanced therapy in 78/82(95%) of the cohort. Thirty-four out of 82 patients (41%) received an optimized antiTFN-a regimen, as well as 34/82 (41%) were treated with combo-therapy with immunosuppressants. AntiTNF-a was withdrawn in 35/82 (42.7%) patients during follow-up, and the rate of adverse events that led to discontinuation of the drug was 16% (13/82). When we compared the rate of primary and secondary non-response, persistence of the antiTNF-a therapy or use of combo-therapy, we did not find significant differences between patients by HLA-DQA1*05 status. On the other hand, the rate of infusion reactions, development of anti-TNF antibodies or adverse events that led to drug withdrawal were also similar among patients HLA-DQA1*05 positive or negative. Only the need of optimized antiTNF-a was more frequent among patients HLA-DQA1*05 positive (19(54.3%) vs. 15 (31.9%), p= 0.028).

Conclusion
In our real-life cohort of IBD patients treated with antiTNF-a, being an HLA-DQA1*05 carrier did not act as a predictor of loss of response, either primary or secondary. The safety of anti-TNF treatment has also not been influenced by the variant. However patients HLA-DQA1*05 positive required optimized antiTNF-a regimen more frequently.